Cytochrome P450 2D6 enzyme neuroprotects against 1‐methyl‐4‐phenylpyridinium toxicity in SH‐SY5Y neuronal cells

Cytochrome P450 (CYP) 2D6 is an enzyme that is expressed in liver and brain. It can inactivate neurotoxins such as 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine, 1,2,3,4‐tetrahydroisoquinoline and β‐carbolines. Genetically slow CYP2D6 metabolizers are at higher risk for developing Parkinson’s disease, a risk that increases with exposure to pesticides. The goal of this study was to investigate the neuroprotective role of CYP2D6 in an in‐vitro neurotoxicity model. SH‐SY5Y human neuroblastoma cells express CYP2D6 as determined by western blotting, immunocytochemistry and enzymatic activity. CYP2D6 metabolized 3‐[2‐(N,N‐diethyl‐N‐methylammonium)ethyl]‐7‐methoxy‐4‐methylcoumarin and the CYP2D6‐specific inhibitor quinidine (1 μm ) blocked 96 ± 1% of this metabolism, indicating that CYP2D6 is functional in this cell line. Treatment of cells with CYP2D6 inhibitors (quinidine, propanolol, metoprolol or timolol) at varying concentrations significantly increased the neurotoxicity caused by 1‐methyl‐4‐phenylpyridinium (MPP⁺) at 10 and 25 μm by between 9 ± 1 and 22 ± 5% (P < 0.01). We found that CYP3A is also expressed in SH‐SY5Y cells and inhibiting CYP3A with ketoconazole significantly increased the cell death caused by 10 and 25 μm of MPP⁺ by between 8 ± 1 and 30 ± 3% (P < 0.001). Inhibiting both CYP2D6 and CYP3A showed an additive effect on MPP⁺ neurotoxicity. These data further support a possible role for CYP2D6 in neuroprotection from Parkinson’s disease‐causing neurotoxins, especially in the human brain where expression of CYP2D6 is high in some regions (e.g. substantia nigra).